Accolade (NASDAQ:ACCD) Posts Earnings Results, Beats Estimates By $0.13 EPS

Accolade (NASDAQ:ACCD) announced its quarterly earnings data on Thursday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.13, Briefing.com reports. Accolade had a negative return on equity of 22.53% and a negative net margin of 24.09%. The business had revenue of $110.50 million during the quarter, compared to the consensus estimate of $105.22 million. During the same period in the previous year, the company posted ($0.52) earnings per share. The business’s revenue for the quarter was up 18.6% on a year-over-year basis. Accolade updated its FY 2025 guidance to EPS and its Q2 2025 guidance to EPS.

Accolade Stock Performance

NASDAQ ACCD opened at $3.71 on Friday. The business’s 50-day moving average price is $7.20 and its 200 day moving average price is $9.70. Accolade has a twelve month low of $3.70 and a twelve month high of $15.36. The company has a market capitalization of $296.84 million, a PE ratio of -4.80 and a beta of 2.10. The company has a current ratio of 2.64, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Insider Transactions at Accolade

In other news, CAO Colin Mchugh sold 5,543 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $6.62, for a total value of $36,694.66. Following the transaction, the chief accounting officer now directly owns 50,177 shares in the company, valued at approximately $332,171.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 14,746 shares of company stock worth $104,586 in the last three months. 8.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ACCD shares. Wells Fargo & Company decreased their target price on Accolade from $12.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 30th. Guggenheim reduced their price objective on Accolade from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Stifel Nicolaus reduced their price objective on Accolade from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Needham & Company LLC reissued a “buy” rating and issued a $13.00 target price on shares of Accolade in a report on Monday. Finally, Truist Financial dropped their target price on Accolade from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.93.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.